Striatal neurochemical changes and motor dysfunction in mipafox-treated animals.
5 mg/kg mipafox [N,N'-bis(1-methylethyl)phosphordiamidic fluoride] was administered s.c. daily for 60 days in rats. The animals developed motor dysfunction-muscle twitchings, fasciculations and slight ataxia towards the end of the experimental period; the motor dysfunction was accompanied by neurochemical changes in the corpus striatum which included significantly reduced levels of cholinesterase, neurotoxicesterase, dopamine and GABA. The neurochemical imbalance in the corpus striatum may be related to motor dysfunction in mipafox-treated animals.
Matin
M A
MA
Hussain
K
K
D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D002265:Carboxylic Ester Hydrolases / Q000378:metabolism; D003342:Corpus Striatum / Q000378:metabolism*; D004298:Dopamine / Q000032:analysis; D007531:Isoflurophate / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D008297:Male; D009069:Movement Disorders / Q000139:chemically induced*; D018377:Neurotransmitter Agents / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D005680:gamma-Aminobutyric Acid / Q000032:analysis
D018377:Neurotransmitter Agents; D007531:Isoflurophate; C005238:mipafox; D005680:gamma-Aminobutyric Acid; D002265:Carboxylic Ester Hydrolases; C021859:neurotoxic esterase; D000110:Acetylcholinesterase; D004298:Dopamine